Compare RENT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | CRDF |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.3M | 187.9M |
| IPO Year | 2021 | 2012 |
| Metric | RENT | CRDF |
|---|---|---|
| Price | $6.51 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 68.4K | ★ 1.7M |
| Earning Date | 03-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.11 | N/A |
| EPS | ★ 5.10 | N/A |
| Revenue | ★ $306,200,000.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.72 | N/A |
| P/E Ratio | $1.23 | ★ N/A |
| Revenue Growth | 2.68 | ★ 49.61 |
| 52 Week Low | $3.69 | $1.48 |
| 52 Week High | $10.13 | $4.56 |
| Indicator | RENT | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 34.89 |
| Support Level | $4.52 | $1.48 |
| Resistance Level | $6.71 | $1.68 |
| Average True Range (ATR) | 0.44 | 0.09 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 42.00 | 43.75 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.